A case of Mycobacterium goodiiprosthetic valve endocarditis in a non-immunocompromised patient: use of 16S rDNA analysis for rapid diagnosis by Göran Jönsson et al.
CASE REPORT Open Access
A case of Mycobacterium goodii prosthetic valve
endocarditis in a non-immunocompromised
patient: use of 16S rDNA analysis for rapid
diagnosis
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Abstract
Background: Mycobacterium goodii is a rare cause of significant infection. M. goodii has mainly been associated
with lymphadenitis, cellulitis, osteomyelitis, and wound infection.
Case presentation: A case of a 76-year-old Caucasian female is presented. The patient developed a prosthetic
valve endocarditis caused by M. goodii. She had also suffered from severe neurological symptoms related to a
septic emboli that could be demonstrated as an ischemic lesion found on CT of the brain. Transesophageal
echocardiography verified a large vegetation attached to the prosthetic valve. Commonly used blood culture
bottles showed growth of the bacteria after 3 days.
Conclusions: Although M. goodii is rarely involved in these kinds of severe infections, rapidly growing mycobacteria
should be recognized during conventional bacterial investigations and identified by molecular tools such as analysis
of 16S rDNA. Species identification of nontuberculous mycobacteria is demanding and is preferably done in
collaboration with a mycobacterial laboratory. An early diagnosis provides the opportunity for adequate treatment.
In the present case, prolonged antimicrobial treatment and surgery with replacement of the prosthetic valve was
successful.
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Background
Mycobacterium goodii was identified in 1999 as a rap-
idly growing non tuberculous mycobacteria (NTM)
species related to the Mycobacterium smegmatis group
isolated from human wound infections [1]. M. goodii
has previously been associated with sporadic cases of
cellulitis, osteomyelitis, infected pacemaker sites, lipoid
pneumonia [1,2], and bursitis [3]. M. goodii has also been
related to minor hospital outbreaks in patients receiving
surgical implants [4]. However, there has been no
reported case of native or prosthetic valve endocarditis
due to M. goodii. Since 1978, there are at least 9 cases
reported in the literature with native and prosthetic valve
endocarditis recognized to belong to the M. fortuitum
group [5]. Some of these patients were probably more
susceptible to this type of infection due to underlying
medical conditions such as HIV, intravenous drug use
and renal failure [5]. Here we present a case of pros-
thetic valve endocarditis caused by M. goodii.
Case presentation
A 76-year-old Caucasian female was admitted to our
hospital in September 2009 with a sudden onset of dys-
pnea that had emerged during dancing a foxtrot. She was
previously remarkably healthy and lived a very active life
with hobbies like dancing and gardening. On initial as-
sessment at the Emergency Department, she had no
history of chills, fever, night sweats, cough or chest
pain. Physical examination revealed a severe respiratory
distress requiring oxygen treatment. Ultrasound exam-
ination of the heart was consistent with a mitral valve
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insufficiency caused by a rupture of chordae tendineae.
Coronary angiography was normal except for a signifi-
cant proximal stenosis found in D2. Eleven days after
admission (September 28) the patient received a bio-
logical mitral valve replacement (Edward Magna Nr 25,
Edwards Lifesciences Corp, Irvine, CA, USA) and a
coronary artery bypass of D2 was also performed. The
postoperative course was uneventful, and the patient
was discharged from the hospital in good health on the
5th of October.
On the 15th of January 2010, the patient was readmit-
ted to the Department of Neurology. The patient had
suffered from general fatigue for at least 2–3 weeks, and
had experienced slurred speech, poor balance, and dis-
orientation to time and places for at least 24 hours. Ini-
tial neurological examination showed difficulty in
walking due to poor balance. She was afebrile. Com-
puted tomography (CT) of the brain revealed an ische-
mic lesion of the right cerebellar hemisphere, and she
was assumed to have suffered from episodes of transient
ischemic attacks and stroke. No blood cultures were
drawn, and the patient was discharged. Further investi-
gation as an out-patient revealed normal results from ca-
rotid Doppler, electroencephalography, and Holter
ambulatory electrocardiography.
The patient was readmitted to the Emergency Depart-
ment on the 2nd of February 2010. She was again con-
fused with slurred speech, complained about general
weakness, and had now a temperature of 40.2°C. Her
heart rate was 99 beats per minute without cardiac mur-
murs, the blood pressure was 100/45 mmHg, and fur-
ther physical examination was normal. Laboratory
investigations showed the following results: hemoglobin
101 g/L, leukocyte count 7.1 × 109/L (ref. 4–10 × 109/L),
platelet count 155 × 109/L (ref. 140–400 × 109/L), and C-
reactive protein (CRP) was 110 mg/L (ref. <3.0 mg/L).
Serum sodium, potassium and creatinine were within
normal ranges. After securing four sets of blood cul-
tures, the patient was initially given empirical treatment
for bacterial meningitis with intravenous ampicillin,
cefotaxime, and betamethasone. However, she developed
no stiffness of the neck and further analysis of cerebro-
spinal fluid showed no signs of meningitis. Also, chest
radiography was normal, and CT of the brain did not re-
veal any new lesions including abscesses. Transesopha-
geal echocardiography (TEE) was inconclusive with an
unclear structure found floating in the left auricle. No
vegetation or insufficiency was described. The patient
rapidly improved, became afebrile and was discharged
after two days of hospitalization. She was prescribed oral
amoxicillin 500 mg t.i.d. for 7 days.
After five days (February 9) the patient returned with
general fatigue, confusion and fever of 40°C, again with
similar results of physical, neurological and laboratory
examinations as on February 2nd. A new TEE demon-
strated a large (13 mm), mobile vegetation attached to
the prosthetic mitral valve. Treatment for endocarditis
with cefotaxime and gentamicin was instituted. The
blood cultures, drawn on the 2nd of February, were
inoculated in aerobic and anaerobic blood culture bottles
(bioMerieux, FAN-bottles, Marcy l’Etoile, France), and
one aerobic bottle indicated growth after 3 days. A
catalase positive Gram-positive rod with partial Gram-
staining was identified on blood agar plates. It was
initially considered to be a diphteroid rod with doubtful
clinical significance, but when all four blood culture sets
subsequently showed growth of multidrug-resistant
Gram-positive rods, 16S rDNA PCR analysis was per-
formed [6]. Sequence analysis covering ~800 bp of the
16S rRNA gene demonstrated a complete homology
with M. goodii isolates from GenBank. Once it was clear
that the isolate was a rapidly growing mycobacterial spe-
cies, the strain was sent to the mycobacterial section at
the clinical microbiology laboratory. Species identifica-
tion of M. goodii using 16S rDNA sequencing was con-
firmed using GenotypeW Mycobacterium CM and AS
assays (HAIN Lifescience, Nehren, Germany). Anti-
microbial susceptibility testing (AST) was performed in
two stages, first at the conventional bacteriology section,
followed by additional testing at the mycobacteriology
section. All AST were performed with use of EtestW
(bioMérieux, Marcy l’Etoile, France) on Mueller Hinton
agar. At this stage, the treatment was changed to mero-
penem combined with gentamicin and ciprofloxacin
(Figure 1) based on the antibiotic susceptibility pattern
(Table 1). The fever resolved and CRP declined from
65 mg/L to 38 mg/L.
The patient went through mitral valve replacement sur-
gery on the 19th of February, again with a similar bio-
logical prosthetic valve (Edward Magna Nr 25, Edwards
Lifesciences Corp, Irvine, CA, USA). The rationales
for this decision were the finding of a prosthetic valve
endocarditis due to a highly resistant microorganism
and a large vegetation with a risk of new episodes of
embolization. At surgery a vegetation was found and there
were signs of infection surrounding the prosthetic valve
ring. Cultures from the vegetation showed no growth, but
16S rDNA gene sequencing was consistent with the
findings of M. goodii. After surgery there was a dramatic
improvement of the patient’s general condition. Merope-
nem was replaced by ampicillin due to lower MIC-value
(Table 1), but during the third week of treatment CRP was
repeatedly found to be about 70 mg/L (Figure 1). The
antibiotic treatment was changed in accord with the sus-
ceptibility pattern that favoured the combination of tigecy-
cline and ciprofloxacin (Table 1). The following two weeks
CRP dropped to 6.1 mg/L. The patient was discharged on
March 23 in good health and continued with the
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combination of oral doxycycline and ciprofloxacin for an
additional eleven weeks. She was followed clinically and
with laboratory analyses for 30 weeks. CRP remained at a
normal level and repeatedly drawn blood cultures showed
no bacterial growth (Figure 1).
Conclusions
Infective endocarditis caused by M. goodii has to our
knowledge not previously been described. M. goodii is a
rapidly growing NTM, and visible colonies are formed
on Loewenstein-Jensen culture medium within 7 days of
incubation [7]. Microbiological diagnosis is obtained by
microscopy for acid-fast bacilli on secretions or biopsy,
and by culture. Species identification of NTM is
demanding and often a combination of biochemical and/
or molecular methods needs to be applied. In many
cases 16S rDNA-sequencing is enough for species identi-
fication but a number of NTMs have similar gene
sequences enhancing the importance of several different
approaches to identify NTMs at a species level [8].
NTMs are found in the natural environment through-
out the world and include more than 135 different spe-
cies. Rapidly growing NTMs have been isolated from
potable and natural water, and in soil. They can also be
isolated from contaminated tap water. There are evi-
dence suggesting that nosocomial transmission have oc-
curred for M. fortuitum, M. chelonae, M. abscessus, and
M. goodii [4,9], which resulted in conditions ranging
from harmless colonization to invasive infection. One
explanation to this problem might be that many of the
nontuberculous mycobacteria are resistant to disinfec-
tants [9], and an effective disinfectant or antiseptic
against M. goodii has not been reported.
NTM infections in surgical patients have been
reported in a wide variety of settings. The use of colo-
nized aqueous solutions and inadequate sterilization or
disinfection of surgical equipment are often factors
involved in these infections. M. fortuitum and M. chelo-
nae have caused multiple outbreaks of sternal wound in-
fection and endocarditis after cardiac surgery. One
outbreak was traced to contaminated tap water that had
Figure 1 Comparison between C-reactive protein (CRP) levels and treatments given over time. The first antibiotic regime was cefotaxime
and gentamicin administered for three days. After the prosthetic valve surgery, the patient received antibiotics for four months. Twelve weeks
after surgery, CRP was found to be repeatedly at a normal level. Only the initially drawn blood cultures showed growth of Mycobacterium goodii.
The broken line indicates CRP≤ 3.0 g/L.
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been used to make cardioplegia solution. The highest
mortality rates have been reported in patients with pros-
thetic valve replacements [10-13]. The implantation of
porcine heart valves colonized with M. chelonae during
manufacture resulted in pericarditis and endocarditis
[14,15]. M. smegmatis, M. chelonae, M. gordonae, and
M. fortuitum have caused isolated cases of prosthetic
valve endocarditis in the immediate postoperative
period. M. chelonae, M. fortuitum, and M. smegmatis
have been retrieved in isolated cases of postoperative
sternal wound infections and mediastinitis [13,16,17]. M.
chelonae has been isolated from vein graft harvest site
infections after cardiac bypass surgery [18].
Our patient had received a prosthetic mitral valve
four months before the infection gave any obvious
symptoms such as fever. It seems likely that our patient
had a prolonged, indolent infection that was acquired
during surgery, as indicated by reports of porcine aortic
valves contaminated by other NTMs [14,15]. During
the observed period (January 2010 to October 2011),
there was no other patient found with a M. goodii in-
fection at our hospital, suggesting no obvious environ-
mental source of contamination. However, no further
investigation regarding an environmental source was
performed, and thus it can not be determined whether
the valve prosthesis was contaminated before or during
surgery. In retrospect, our patient had never really
regained her strength after the first operation and had
suffered from general fatigue. Also, we believe that her
neurological symptoms already on January 15th, includ-
ing the ischemic lesion found on CT of the brain, rep-
resent embolic lesions from the prosthetic endocarditis.
The very late onset of clear signs of infection in our
patient is different from what has been previously
described in patients with M. goodii associated surgical
implant infections (3 days-4 weeks) [4].
Antimicrobial susceptibility data for M. goodii are
sparse. Brown et al. [1] showed that all M. goodii iso-
lates were susceptible to amikacin, doxycycline, cipro-
floxacin, and sulfamethoxazole, and were variably
susceptible to cefoxitin and clarithromycin. These bac-
teria are usually also susceptible to ethambutol and ex-
hibit good in vitro susceptibility to gatifloxacin and
ciprofloxacin [2]. Commonly used antimicrobials in-
clude trimethoprim/sulfamethoxazole, doxycycline, and
ciprofloxacin. Intravenous amikacin and imipenem have
been used for severe cases [8]. However, there are few
data on the clinical validation of using susceptibility
breakpoints of tested drugs. Notably, tigecycline has to
our knowledge not been previously used in the treat-
ment of M. goodii disease, and in the present case we
believe that tigecycline treatment contributed to the
successful outcome. In prosthetic endocarditis, surgical
excision of the valve is probably necessary besides treat-
ment with a combination of antibiotics for about
4 months [8]. The in vitro susceptibility pattern
observed for M. goodii in this investigation is consistent
with previously reported findings. Notably, there are
specific culturing techniques for the recovery of myco-
bacterial blood stream infections which are used when
mycobacterial infection is highly suspected, but this
case highlights that commonly used blood culture bot-
tles such as bioMerieux, FAN-bottles may be sufficient
to detect rapidly growing NTM.
In summary, M. goodii is a rapidly growing myco-
bacterium increasingly recognized as an important
human pathogen. It is most commonly implicated in
surgical site and posttraumatic infections, but is also
associated with respiratory infections in patients with
lipoid pneumonia. Identification of the organism is
best accomplished by molecular techniques and 16S
rDNA-sequencing is an example of a useful analysis
in suspected NTM disease. Our patient history high-
lights the importance of rapidly performed testing for
mycobacteria in prosthesis-related infections.
Consent
Written informed consent was obtained from the patient
for publication of this case and any accompanying
Table 1 The antibiotic resistance pattern of the
Mycobacterium goodii isolated from blood cultures






















Jönsson et al. BMC Infectious Diseases 2012, 12:301 Page 4 of 5
http://www.biomedcentral.com/1471-2334/12/301
imaged. A copy of the written consent is available by
Series Editor of this journal.
Abbreviations
CRP: C-reactive protein; CT: Computed tomography; PCR: Polymerase chain
reaction; NTM: Non tuberculous mycobacteria; TEE: Transesophageal
echocardiography.
Competing interests
Prof. Bertil Christensson is a member of Pfizer Advisory Board for Bacterial
Infections. Johan Rydberg, Erik Sturegård and Göran Jönsson declare no
competing interests.
Authors’ contribution
All authors of this case report made substantial contributions to conception
and design. GJ and BC drafted the manuscript. JR and ES were involved in
the microbiological investigations. All authors revised the manuscript
critically, read, and approved the final version.
Author details
1Department of Clinical Sciences, Division of Infection Medicine, University
Hospital of Skåne, Lund SE-221 85, Sweden. 2Department of Laboratory
Medicine, Division of Microbiology, Lund SE-221 85, Sweden. 3Department of
Clinical Microbiology, Laboratory Medicine Skåne, Lund University, Malmö
SE-205 02, Sweden.
Received: 8 December 2011 Accepted: 29 October 2012
Published: 14 November 2012
References
1. Brown BA, Springer B, Steingrube VA, Wilson RW, Pfyffer GE, Garcia MJ,
Menendez MC, Rodriguez-Salgado B, Jost KC Jr, Chiu SH, et al:
Mycobacterium wolinskyi sp. nov. and Mycobacterium goodii sp. nov.,
two new rapidly growing species related to Mycobacterium smegmatis
and associated with human wound infections: a cooperative study from
the International Working Group on Mycobacterial Taxonomy. Int J Syst
Bacteriol 1999, 49(Pt 4):1493–1511.
2. Brown-Elliott BA, Wallace RJ Jr: Clinical and taxonomic status of
pathogenic nonpigmented or late-pigmenting rapidly growing
mycobacteria. Clin Microbiol Rev 2002, 15(4):716–746.
3. Friedman ND, Sexton DJ: Bursitis due to Mycobacterium goodii, a
recently described, rapidly growing mycobacterium. J Clin Microbiol 2001,
39(1):404–405.
4. Ferguson DD, Gershman K, Jensen B, Arduino MJ, Yakrus MA, Cooksey RC,
Srinivasan A: Mycobacterium goodii infections associated with surgical
implants at Colorado hospital. Emerg Infect Dis 2004, 10(10):1868–1871.
5. Spell DW, Szurgot JG, Greer RW, Brown JW 3rd: Native valve endocarditis
due to Mycobacterium fortuitum biovar fortuitum: case report and
review. Clin Infect Dis 2000, 30(3):605–606.
6. Kahn F, Linder A, Petersson AC, Christensson B, Rasmussen M: Axillary
abscess complicated by venous thrombosis: identification of
Streptococcus pyogenes by 16S PCR. J Clin Microbiol 2010,
48(9):3435–3437.
7. Petrini B: Non-tuberculous mycobacterial infections. Scand J Infect Dis
2006, 38(4):246–255.
8. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F,
Holland SM, Horsburgh R, Huitt G, Iademarco MF, et al: An official ATS/IDSA
statement: diagnosis, treatment, and prevention of nontuberculous
mycobacterial diseases. Am J Respir Crit Care Med 2007, 175(4):367–416.
9. Wallace RJ Jr, Brown BA, Griffith DE: Nosocomial outbreaks/pseudo-
outbreaks caused by nontuberculous mycobacteria. Annu Rev Microbiol
1998, 52:453–490.
10. Szabo I, Sarkozi K: Mycobacterium chelonae endemy after heart surgery
with fatal consequences. Am Rev Respir Dis 1980, 121:607.
11. Hoffman PC, Fraser DW, Robicsek F, O’Bar PR, Mauney CU: Two outbreaks
of sternal wound infection due to organisms of the Mycobacterium
fortuitum complex. J Infect Dis 1981, 143(4):533–542.
12. Kuritsky JN, Bullen MG, Broome CV, Silcox VA, Good RC, Wallace RJ Jr:
Sternal wound infections and endocarditis due to organisms of the
Mycobacterium fortuitum complex. Ann Intern Med 1983, 98(6):938–939.
13. Robicsek F, Daugherty HK, Cook JW, Selle JG, Masters TN, O’Bar PR,
Fernandez CR, Mauney CU, Calhoun DM: Mycobacterium fortuitum
epidemics after open-heart surgery. J Thorac Cardiovasc Surg 1978,
75(1):91–96.
14. Laskowski LF, Marr JJ, Spernoga JF, Frank NJ, Barner HB, Kaiser G, Tyras DH:
Fastidious mycobacteria grown from porcine prosthetic-heart-valve
cultures. N Engl J Med 1977, 297(2):101–102.
15. Levy C, Curtin JA, Watkins A, Marsh B, Garcia J, Mispireta L: Mycobacterium
chelonei infection of porcine heart valves. N Engl J Med 1977,
297(12):667–668.
16. Wallace RJ Jr, Nash DR, Tsukamura M, Blacklock ZM, Silcox VA: Human
disease due to Mycobacterium smegmatis. J Infect Dis 1988, 158(1):52–59.
17. Syed AU, Hussain R, Bhat AN, al Rasheed M, al Qethami H, al Faraidi Y, al
Fagih MR: Mediastinitis due to Mycobacterium fortuitum infection
following Fontan operation in a child. Scand Cardiovasc J 1997,
31(5):311–313.
18. Engelhardt E, Feldmann R, Skaria A, Salomon D: Postoperative infection
with Mycobacterium chelonae. Hautarzt 1996, 47(11):863–866.
doi:10.1186/1471-2334-12-301
Cite this article as: Jönsson et al.: A case of Mycobacterium goodii
prosthetic valve endocarditis in a non-immunocompromised patient:
use of 16S rDNA analysis for rapid diagnosis. BMC Infectious Diseases
2012 12:301.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Jönsson et al. BMC Infectious Diseases 2012, 12:301 Page 5 of 5
http://www.biomedcentral.com/1471-2334/12/301
